Want to join the conversation?
$OREX 2Q15 Q&A: Duncan of Piper Jaffray asked to give color on the driver to superior prescription performances. Tom answered it is good solid growth of overall market and branded market coupled with good, steady share penetration which is really driven by differentiated product profile. Strong pricing program and patient support program.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?